The Difference is in the Data
MMS is the data-focused CRO driving pharmaceutical and biotech innovation with unparalleled regulatory expertise and technological innovation. Our experts across four continents are available to support your programs 24 hours a day with an industry-leading Sponsor satisfaction rating.
Full Service Biometrics
When your destination is a healthier world, making intelligent connections between data, technology, and services is your roadmap.
Regulatory Submissions
From the Investigational New Drug (IND) application stage through New Drug Applications (NDA), our deep expertise ensures that your drug development process is efficient, compliant, and strategically aligned with standards set by global health authorities.
Safety & Risk Management
Comprehensive pharmacovigilance, safety and risk management from Phase 1 through post approval, tailored to your specific needs.
Therapeutic Expertise
From industry-firsts to well-researched indications, MMS brings specialized knowledge in rare diseases, psychedelics, oncology and radiopharmaceuticals, central nervous system (CNS) disorders, and many others.
Functional Service Provider (FSP)
A flexible and scalable FSP model, providing the right level of oversight, scale, and governance to achieve your long- and short-term strategic goals.
What Differentiates MMS From Other CROs?
Responsive
MMS is more responsive, taking responsibility for the success of every project with consistent staff and proactive solutions that exceed the expectations of a CRO partner.
Adaptable
MMS is more adaptable, knowing your satisfaction and top outcomes are dependent on our ability to remain nimble and make smart decisions based on scientifically-sound data.
Focused
MMS is more focused, providing data-centric solutions and innovative technology and processes that help accelerate and de-risk the development and approval of your therapy.
This team never stopped working towards our deadline, and from day one, we were impressed with the efficient and smart decisions brought forth by MMS to bring this drug to market.
The choice in collaborating with MMS to meet this milestone… was simple, given their deep scientific knowledge and strategic resource models.
I cannot thank the MMS Team for the outstanding support you’re providing to ensure these are prepared for submission. I am continuously impressed with the MMS team and truly value the partnership.
AI and Technology
Sponsors can rest assured knowing that MMS will bring new levels of innovation and technology to our processes and deliverables.
in Michigan
Colleagues
Globally
Applications in the
Last 5 Years
trust
Upcoming Events
MMS Insights
webinar
September 26th, 2024
Regulatory Pathways for Nonprescription Drugs: A Deep Dive into OTC Monograph Reform and FDA Guidance
webinar
September 12th, 2024
No Stone Unturned: Optimizing the Use of Expedited Pathways and Oncology Center of Excellence Programs to Optimize Drug Development in Oncology
perspectives
July 30th, 2024
The Critical Role of Quality Control (QC) – Medical Writing and Beyond
perspectives
July 23rd, 2024
PSI 2024 Ignited Conversations on External Data Sources, Requirements for Estimands, and Bayesian Methodology for Statisticians in Pharma
news
July 17th, 2024
Industry Veteran Ben Dudley Joins MMS as Chief Commercial Officer (CCO) to Drive Continued Growth for the Data-focused Clinical Research Organization
perspectives
July 16th, 2024
Key Steps to Successful CMC Authoring of IND and IMPD Submissions
webinar
July 11th, 2024
The Rising Burden of Pharmacovigilance (PV) Requirements in Early Drug Development
perspectives
July 9th, 2024
Managing RTOR Submissions: How to Run a Successful Race from the Top Line Starting Line
perspectives
July 2nd, 2024
Part 1: RWD Noninterventional Study Design and FDA Engagement Opportunity for Early Stage Oncology
webinar
June 26th, 2024
A Psychedelic Shift: Assessing the Potential for Nonmedical Use in a Changing Regulatory Landscape
perspectives
June 21st, 2024
Peer-Reviewed Journal Articles: The Crucial Role of Publication in the Pharmaceutical Industry
perspectives
June 14th, 2024
A Structured Approach to Benefit-Risk Assessment Throughout Product Development in the Pharmaceutical Industry
perspectives
June 6th, 2024
Datacise and Diversity in Patient Enrollment: Combining Geospatial and Demographic Data to Aid Site Selection
perspectives
May 29th, 2024
Confined Deferrals in Clinical Trial Applications: Anticipating the Revised EU CTR Transparency Rules
perspectives
May 21st, 2024
Psychedelics and Regulatory Considerations Part II: A Shift in Lexicon and Implications of “Nonmedical Use” On Labelling